Objective. This study identified sociodemographic, substance use, and multiple opioid prescriber and dispenser risk factors among drug overdose decedents in Rhode Island, in response to an increase in overdose deaths (ODs) involving fentanyl.
Introduction
From 2009 to 2012, Rhode Island experienced a steady increase in drug overdose deaths (OD) [1] . Most involved nonprescription, illicit drugs (e.g., heroin, cocaine), which accounted for 53% of all ODs reported in 2012 (N ¼ 183) [1] . In 2013, a small (N ¼ 14) temporary increase in ODs from acetyl fentanyl-an illegally produced opioid analog-was detected in northern Rhode Island [2] . Subsequently during January 2014, Rhode Island experienced twice as many ODs as in January of previous years. These deaths were mostly among people who inject drugs and involved a different synthetic opioid-fentanyl.
First synthesized in the 1960s as a general anesthetic [3] , fentanyl is 50 to 100 times more potent than morphine and 30 to 50 times more potent than heroin [4] . By 1990, and coinciding with physicians being encouraged to prescribe stronger analgesics [5] , fentanyl was initially approved as an analgesic for cancer pain and then expanded to treat chronic pain. Between 1999 and 2002, the annual number of fentanyl prescriptions in the United States increased 150%, reaching 4.6 million [6] . Today, fentanyl is used for severe, chronic pain control.
As with other pharmaceutical opioids, fentanyl can be abused and has contributed to the national epidemic of drug poisoning deaths [5] . Additionally, illicitly manufactured fentanyl-produced by clandestine laboratories since the late 1970s and commonly consumed by heroin users-has been associated with ODs [7] . Between April 2005 and March 2007, over 1,000 ODs involving illicitly manufactured fentanyl were identified in New Jersey; Maryland; Chicago, Illinois; Detroit, Michigan; and Philadelphia, Pennsylvania [8] . The desire for higher-potency opioids in the face of heroin's declining purity led to the distribution of fentanyl and fentanyllaced heroin, with a subsequent spike in illicit fentanyl ODs throughout the 2000s [9, 10] . Heroin abuse often occurs in the broader context of polysubstance use, especially prescription opioids and cocaine [11] .
Study Purpose
In February 2014, the Rhode Island Department of Health (RIDOH) requested the Centers for Disease Control and Prevention's (CDC's) assistance in defining and characterizing a spike in ODs involving fentanyl. This study explored three types of risk factors for these ODs: 1) sociodemographic characteristics; 2) substance use and abuse, especially opioid abuse; and 3) visiting multiple prescribers and dispensers to obtain opioid prescriptions (considered multiple provider episodes). Findings may help RIDOH target educational messages and review their OD prevention strategies. Based on expert advice from local and federal law enforcement, health care, public health, and drug rehabilitation and treatment professionals, it was hypothesized that these OD deaths involving fentanyl were associated with illicit substance use.
Methods
This cross-sectional study was conducted as part of an epidemiological public health emergency investigation in response to the increase in ODs involving fentanyl reported in Rhode Island between November 2013 and March 2014. As such, the CDC National Center for Injury Prevention and Control determined that human research regulations did not apply.
Study Sample
The study population consisted of all ODs reviewed by the Rhode Island Office of the State Medical Examiners (OSME) between January 1, 2012, and March 31, 2014, for which the reported manner of death was accidental, pending determination, or undetermined (N ¼ 630). This expanded time frame allowed for the assessment of whether the increase in fentanyl-related deaths constituted an outbreak. Children age 0 to 15 years (N ¼ 9), in absentia medical examiner reviews (N ¼ 15), pending cases that were ad hoc determined by the Chief Medical Examiner not to be ODs (N ¼ 40), and suicides (N ¼ 40) were excluded. The final sample size was 536 decedents (Figure 1 ).
Data Sources
This study comprised data from four RIDOH data sources: 1) OSME's charts (electronic and hardcopy); 2) Rhode Island Office of Vital Records' death certificates; 3) Rhode Island State Health Laboratory toxicology reports; and 4) Rhode Island's Prescription Monitoring Program (PMP) database. OSME's charts contained sociodemographic, incident, autopsy, toxicology, and third party reports of drug use for each decedent. OSME compiled this information from medical examiners' (MEs') reports, toxicology reports, emergency medical services and/or hospital reports, police reports, medical records, and other information provided to or requested by the ME to determine the cause of death. Rhode Island has a centralized ME system. All autopsy reports are reviewed by the Chief ME, who certifies the cause of death based on the advice provided by the lead ME for each case.
Death certificates contained sociodemographic information on the decedent. Toxicology reports contained preliminary and confirmatory results of any toxicology tests performed on postmortem samples collected during autopsy or external inspection, and/or available antemortem samples collected during terminal hospitalizations, when the decedent was hospitalized for more than a few minutes. days of death (n = 6)** Figure 1 Study population: drug overdose deaths in Rhode Island, January 2012 to March 2014. OD ¼ overdose death; RI OSME ¼ Rhode Island Office of the State Medical Examiners; Rx ¼ Prescription. *RI OSME reports the manner of death for drug overdoses to be accidental, pending, undetermined, or suicide. For the purposes of this analysis, suicide deaths were excluded. † Includes five decedents with a fentanyl-related primary or contributing cause of death, and one decedent whose cause of death was pending/nonspecific.
Increase in Fentanyl Overdose Deaths
Rhode Island's PMP database contained information on any prescriptions filled by the decedents at Rhode Island pharmacies or dispensers (i.e., product, strength, quantity, days, prescriber, pharmacy). All Rhode Island pharmacies and mail order pharmacies licensed to do business in Rhode Island have been required to report Schedule II-IV prescription dispensing information (e.g., opioids) to the Rhode Island PMP system since July 1, 2013. Physicians are able to access this system to review their patients' prior prescriptions as a tool to prevent overprescribing and drug diversion [12, 13] . Only prescriptions filled within 90 days of the decedent's date of death were considered for this study.
Definitions

Comparison Groups
Illicit fentanyl deaths included decedents for whom fentanyl was listed as an official cause of death or as a contributor on the final autopsy report provided by the Rhode Island OSME yet whom were not prescribed fentanyl. These also included decedents for whom the cause of death was pending or nonspecific, and preliminary toxicology reports identified fentanyl levels to be above the Rhode Island OSME working cutoff detection limit (i.e., enzyme-linked immunosorbent assay [ELISA] > 2 ng/mL), which also allows for the detection of fentanyl analogs [14] . Consistent with the study's hypothesis and expert advice, decedents who filled at least one fentanyl prescription within 90 days of death were excluded from the fentanyl decedents group; only decedents whose deaths involved illicitly produced or acquired fentanyl remained in this group.
Other drug deaths included decedents for whom illicit fentanyl was not listed as an official cause of death or a contributor on the final autopsy report. These decedents also included those for whom the final cause of death was pending or nonspecific, where fentanyl was not detected in toxicology analyses, as well as all decedents who filled fentanyl prescriptions within 90 days of death.
Prescription-Related Variables
Morphine milligram equivalents per day (MME/day) refers to the average morphine milligram equivalents prescribed for daily use, based on all opioid prescriptions dispensed and reported to the PMP system within 90 days of a decedent's date of death. The MME/day for a given prescription is calculated by multiplying an MME conversion factor assigned to each opioid product's National Drug Code [15] by the strength of the product and the number of units prescribed per day (i.e., Strength*(Quantity/Days)*MME Conversion Factor). The number of units prescribed per day is found in the PMP; the MME conversion factors and strengths were obtained from a file compiled by CDC that lists opioids, benzodiazepines, muscle relaxants, and other drugs of interest to those studying prescription drug OD.
Analyses included only the products listed in the CDC MME file [16] ; elixirs and other cough/cold medications, injectables, and opioids infrequently used in outpatient settings were excluded. A decedent was considered to be at increased risk for drug overdose if his/her average MME/day was greater than 100, a frequently utilized cutoff for increased overdose risk [17] [18] [19] [20] .
Prescriber refers to a physician or other health care worker licensed to prescribe opioid medications in the United States and who was identified in PMP records as having prescribed opioid prescriptions to at least one decedent within 90 days of death. Dispenser refers to a pharmacy or other establishment authorized to store and dispense opioid prescriptions in the United States that was identified in PMP records as having dispensed at least one opioid prescription to decedents within 90 days of death. Multiple provider episode refers to a decedent filling opioid prescriptions provided by three or more prescribers, or three or more dispensers, within 90 days of death.
Toxicology Variables
Preliminary (i.e., ELISA) and confirmatory toxicology test results identified substances present in decedents' bodies at the time of death or terminal admission to a hospital. This includes: a) illicit substances (i.e., methamphetamine, cocaine, 6-Monoacetylmorphine [6MAM, a heroin metabolite], and heroin); b) pharmaceutical substances, which may have been used either illicitly or for legitimate medical purposes (i.e., acetaminophen, benzodiazepines, carisoprodol, codeine, methadone, morphine, oxycodone, tricyclic antidepressants, and zolpidem); c) fentanyl-related substances (i.e., acetyl fentanyl, fentanyl, 4-anilino-N-phenethyl-4-piperidine [ANPP, associated with illicit fentanyl manufacture]); and d) opiates, which includes both illicit and pharmaceutical products. As there is no specific toxicology test for heroin, its presence was defined as postmortem toxicological evidence of morphine and at least one of the following requirements: postmortem toxicological evidence of codeine or 6MAM in decedent's body, presence of track marks in a decedent's body, or presence of injection drug paraphernalia at the death scene. An aggregate non-fentanyl-related illicit substance variable was defined as a combined measure of the presence of any nonfentanyl illicit substances on the decedent's remains, excluding all pharmaceutical substances.
Recent Substance Use Variables
Reports of decedents' recent substance use were categorized as prescription drug use (i.e., antidepressant, benzodiazepines, antipsychotics, anticonvulsants, sedative, other) or illicit drug use; the latter is further categorized as any type (i.e., heroin, cocaine, marijuana, methamphetamines, injection drug use, prescription drugs for nonmedical purposes, other) or specifically heroin. This information is based on third party reports (e.g., family, friends, medical records) recorded in decedent's OSME charts.
Sociodemographic Variables
Decedents were also described in terms of their age group (i.e., 17-20, 21-25, 26-35, 36-45, 46-55, 56-65, >65 years), sex (i.e., female, male, unknown), race and ethnicity (i.e., non-Hispanic black, non-Hispanic white, Hispanic, other), marital status (i.e., divorced/widowed, married, single, unknown), and veteran status (i.e., no, yes, unknown).
Data Collection and Analyses
To reduce data entry errors, an electronic data abstraction form to collect data from OSME charts was developed utilizing Epi Info 7 software [21] . Individual PMP data files were downloaded for each decedent from the PMP online system. All data sources were linked based on the unique identifying number assigned to each individual. Data were de-identified for analyses.
Descriptive analyses were conducted for all deaths. Frequencies and proportions were calculated for all sociodemographic, substance use/abuse, and multiple provider episode variables. Bivariate comparisons between potential risk factors and illicit fentanyl decedents and other drug decedents were examined using chisquare or Fisher's exact tests, and t tests assessed significant statistical differences (i.e., P < 0.05) in proportions and means, respectively. The trend of all deaths, highlighting those involving illicit fentanyl, was assessed by week across the study period. All data analyses were conducted using SAS version 9.3 [22] .
Results
In total, 12.9% (N ¼ 69) of the 536 ODs involved illicit fentanyl and 87.1% (N ¼ 467) involved other drugs. Illicit fentanyl deaths included those for which the primary (N ¼ 51) or contributing (N ¼ 1) cause of death involved illicit fentanyl and those with a pending/nonspecific cause of death for whom fentanyl was detected via toxicology tests (N ¼ 23). Decedents that filled fentanyl prescriptions within 90 days of their death (N ¼ 6) were considered part of the other drug group (Figure 1 ).
While illicit fentanyl deaths were reported throughout the study period, two notable increases were identified in Increase in Fentanyl Overdose Deaths correspond to a previously reported outbreak of OD involving acetyl fentanyl in northeast Rhode Island [1] and the increase in ODs involving fentanyl that resulted in this public health response [23] .
Sociodemographic Characteristics
Decedents' ages ranged between 17 and 86 years, with a median age of 45 years. Most decedents were male (68.1%), non-Hispanic white (87.1%), and single (49.3%). Nearly 7% of decedents were known to be military veterans. No statistically significant differences in sex, race and ethnicity, marital or veteran status were found between decedents whose deaths involved illicit fentanyl vs other drugs. However, illicit fentanyl decedents were significantly younger than other drug decedents (P ¼ 0.005); one-third of illicit fentanyl decedents were between 26 and 35 years old (34.8%, N ¼ 24) (Table 1) .
Toxicological Evidence of Substance Use
At the time of death, 63% (N ¼ 336) of all decedents had at least one non-fentanyl-related illicit substance present in their bodies; illicit fentanyl (58.0%) and other drug deaths (63.4%) did not differ in whether they had non-fentanyl-related illicit substances in their toxicology reports. Postmortem toxicological evidence of illicit substance use among all decedents was highest for illicit substances that are frequently injected, such as cocaine and heroin. The difference in toxicological evidence of cocaine among illicit fentanyl (39.1%) and other drug (30.4%) deaths was not statistically significant. However, significantly more other drug (31.9%) than illicit fentanyl (18.8%) deaths had toxicological evidence of heroin consumption (P ¼ 0.000). Additionally, significantly higher proportions of other drug than illicit fentanyl deaths had toxicological evidence of consuming Percentages refer to the proportion of decedents represented within illicit fentanyl and other drug overdose deaths (i.e., column percentages). Bold formatting indicates that differences between illicit fentanyl and other drug decedents are statistically significant. *Denotes Fisher's exact test due to small expected cell counts.
pharmaceutical opioids (i.e., codeine, methadone, morphine, oxycodone) ( Table 2) .
Reported Recent Substance Abuse
Third party reports (e.g., family, friends, medical records) showed that nearly half of all decedents had a recent history of alcohol (48.3%), tobacco (44.6%), or any type of illicit drug use (47.8%). Significantly more illicit fentanyl than other drug decedents were reported to be recent users of any type of illicit drugs (62.3% vs 45.6%, P ¼ 0.002), and specifically heroin (49.3% vs 28.3%, P ¼ 0.000). More than 13% of all decedents had reports of prior OD, and 18.1% were reported to have undergone any type of drug treatment or rehabilitation at least once ( Table 2 ).
Recent Opioid Prescription History
Of the 536 decedents in this study, 186 (34.7%) had at least one opioid prescription filled within 90 days of death-accounting for a nearly identical proportion among illicit fentanyl and other drug deaths (Table 2) . Nearly one-third (32.8%) of all decedents with opioid prescriptions were prescribed more than 100 MME/day, placing them at increased risk for overdose (Table 3) . Among individuals aged 26 to 35 years, only 24.8% (N ¼ 27) filled at least one opioid prescription within 90 days of death, yet 70.4% (N ¼ 19) in this age group were prescribed more than 100 MME/day (mean ¼ 108.7 MME/day; data not shown).
On average, decedents who filled at least one opioid prescription within 90 days of death filled 7.3 (SE ¼ 0.2) opioid prescriptions, with a median 85.1 MME/day (mean ( x) ¼ 45.1, SE ¼ 4.9) during that period. Decedents whose deaths involved other drugs filled significantly more opioid prescriptions ( x6 SE ¼ 7.5 6 0.2 vs 6.0 6 0.4, P ¼ 0.001) with higher MME/per day ( x6 SE ¼ 148.5 6 5.3 vs 114.2 6 9.9, P ¼ 0.039) than those whose deaths involved illicit fentanyl (Table 3) . Illicit fentanyl decedents (29.2%) filled significantly more prescriptions for buprenorphine-an opioid partial antagonist utilized in medication-assisted treatments (MAT) for drug addiction-than other drug decedents (10.5%, P ¼ 0.019) ( Table 4 ). This includes 37.5% of all 26-to 35-year-old illicit fentanyl decedents. Over half of 26-to 35-year-olds also filled oxycodone (59.3%, N ¼ 16) and hydrocodone (51.9%, N ¼ 14) prescriptions within 90 days of death (data not shown). Differences in other opioid prescriptions filled by decedents were not statistically significant (Table 4) .
Multiple Provider Episodes
Most decedents did not have multiple provider episodes (three or more prescribers or dispensers). More than 75% of all decedents who filled opioid prescriptions within 90 days of death (75.8%) obtained these from one to two prescribers; only 24.2% filled opioids provided by three or more prescribers. On average, decedents whose deaths involved other drugs filled prescriptions from more prescribers than illicit fentanyl decedents ( x 6 SE ¼ 2.6 6 0.1 vs 1.9 6 0.2, P ¼ 0.000) ( Table 3) . Young adults aged 26 to 35 years filled opioid prescriptions provided mostly by one to two prescribers (85.2%, N ¼ 23; data not shown).
The majority of decedents who filled opioid prescriptions within 90 days of death (83.9%) did so at one to two dispensers (e.g., pharmacies); 16.1% filled them at three or more dispensers. On average, decedents whose deaths involved other drugs obtained these at more dispensers than illicit fentanyl decedents ( x 6 SE ¼ 2.0 6 0.0 vs 1.5 6 0.1, P ¼ 0.000) ( Table 3) . Young adults aged 26 to 35 years filled these opioid prescriptions at one to two dispensers (81.5%, N ¼ 22; data not shown).
Discussion
Illicit fentanyl deaths were often associated with other illicit drugs that are frequently injected (i.e., heroin, cocaine). Significantly more other drug than illicit fentanyl deaths had toxicological evidence of heroin and various pharmaceutical substances. Yet, third party reports of decedents' recent substance abuse found that significantly more decedents whose deaths involved illicit fentanyl than other drug decedents were recent users of any type of illicit substance, and specifically heroin. Furthermore, the proportion of all decedents who filled opioid prescriptions at levels considered high risk for overdose (>100 MME/day) within 90 days of death is concerning.
Apart from illicit fentanyl decedents being significantly younger than other drug decedents, no other sociodemographic differences were identified. Overall, decedents' sociodemographic characteristics were consistent with the literature; most were non-Hispanic white and male [11] . On average, other drug decedents obtained opioid prescriptions from significantly more prescribers and/or dispensers than illicit fentanyl decedents; multiple provider episodes were not a significant risk factor for illicit fentanyl ODs. This suggests that perhaps illicit fentanyl decedents were further along in the opioid abuse trajectory-relying less on prescription opioids and more on illicit drugs-and at a younger age, compared with other drug decedents.
Significantly more decedents whose deaths involved illicit fentanyl had third party reports of recent illicit drug use-especially of heroin-than other drug decedents.
In fact, nearly 20% of illicit fentanyl deaths had postmortem toxicological evidence of heroin and over one-third had evidence of cocaine in their bodies. Yet significantly more other drug (31.9%) than illicit fentanyl (18.8%) deaths had toxicological evidence of heroin consumption. Limitations in the study's heroin case definition and data sources could have resulted in illicit fentanyl deaths that tested positive for morphine not being classified as heroin positive by the time the study's data were collected (i.e., three out of 16 total morphine-positive illicit fentanyl deaths). Percentages refer to the proportion of decedents represented within illicit fentanyl and other drug overdose deaths (i.e., column percentages). Information on recent substance use, prior overdose, and past drug treatment or rehabilitation was obtained by reviewing each decedent's medical examiner chart, which was based on third party reports (e.g., family members, friends, medical records). Bold formatting indicates that differences between illicit fentanyl and other drug deaths are statistically significant. 6MAM ¼ 6-monoacetylmorphine; ANPP ¼ 4-anilino-N-phenethyl-4-piperidine; C ¼ confirmatory toxicology results; P ¼ preliminary toxicology results (i.e., enzyme-linked immunosorbent assay). *Toxicological heroin evidence was defined as the presence of morphine and at least one of the following requirements: codeine or 6MAM identified in toxicology, presence of track marks in decedent's body, or presence of intravenous drug paraphernalia on the death scene. † Includes the following illicit substances: amphetamine, cannabinoids, cocaine, methamphetamine, 6MAM and heroin, and opiates. Excludes other licit prescription substances presented on the table (e.g., codeine, morphine) that may or may not have been consumed by decedents for legitimate medical purposes. ‡ Fisher's exact test (P values) is presented due to small expected cell counts. Illicit fentanyl deaths were not solely associated with consuming one particular type of nonfentanyl illicit substance. This is consistent with findings from law enforcement investigations, which suggest that illicit fentanyl deaths were mostly associated with illicit injection drug use, with the illicit fentanyl or fentanyl analog being used alone, in place of, at the same time as, or mixed with heroin (e.g., fentanyl-tainted heroin).
It is notable that among all decedents with opioid prescriptions, approximately one-third received more than 100 MME/day within 90 days of death. It is especially concerning that among young decedents (aged 26-35 years) with opioid prescriptions, more than 70% were prescribed more than 100 MME/day. Furthermore, these prescriptions were mostly provided to each decedent by a single prescriber and dispenser, not multiple providers. Additionally, over half of 26-to 35-year-old decedents with opioid prescriptions had been prescribed buprenorphine within the same time period; they were likely receiving MAT for opioid use disorders. Prescriptions for opioids to treat pain should be closely monitored as the combination of buprenorphine with other opioids, whether illicit or prescription, could raise the MME to levels associated with increased risk of overdose. Considering this and the fact that over 34% of illicit fentanyl decedents were aged 26 to 35 years at the time of death, this study's findings disturbingly suggest these young decedents started the opioid abuse trajectory (i.e., prescription opioids to illicit drugs) at a younger age and with a fast-approaching fatal outcome.
Study Limitations
This study was subject to at least four limitations. First, analyses are limited to the data that were abstracted while in the field during this public health emergency response investigation, which occurred while the outbreak was ongoing; some decedents' primary and contributing causes of death were still pending or under review. The study's case definition considers this limitation and allows for illicit fentanyl and other drug decedents to be classified based on preliminary toxicology findings.
Second, inconsistencies in the documentation or availability of information for each decedent could have affected the study's findings, especially decedents' history of substance abuse. This information was gathered by the OSME postmortem, based on third party interviews and/or findings from death scene investigations. As such, our study likely underestimates substance abuse across all decedents.
Third, prescription data were obtained by searching for each decedent by name and date of birth, via Rhode Island's PMP secure query system. This produced records with multiple residential addresses for most decedents. It was not possible to confirm whether these decedents had changed residence or if prescription data for multiple individuals with the same name and date of birth was being produced by Rhode Island's PMP query system. Also, it is not possible to know if all opioid prescriptions filled by decedents were consumed by them, nor if they obtained opioid prescriptions through illicit means (e.g., black market).
Finally, toxicological analyses are unable to distinguish between pharmaceutical and illicitly manufactured fentanyl. Therefore, it was not possible to determine if illicit fentanyl decedents consumed illicitly manufactured fentanyl-a suspected contributor to recent increases in heroin-related deaths [24] -or illicitly acquired pharmaceutical fentanyl.
Conclusions
In 2012, Rhode Island ranked 19th in prescribing opioid pain relievers (89.6 opioid prescriptions per 100 persons) and 17th in prescribing high-dose opioid pain relievers (5.2 per 100) [25] . However, this study's fentanylrelated deaths were associated with the use of illicit fentanyl and other drugs that are frequently injected (e.g., heroin, cocaine). Yet, the high overdose risk levels of MME/day prescribed within 90 days of death are concerning; the risk is even greater when heroin or illicit fentanyl is used simultaneously with prescription opioids. This outbreak occurred within the context of the current heroin epidemic in the United States, driven by the increase in prescription opioid use for nonmedical purposes [11] and heroin's higher availability, lower cost, and increased purity [10, 11] .
Collaborations between law enforcement, public health, health care, and recovery/treatment sectors are needed to reduce access to illicit drugs (e.g., heroin, cocaine), including illicitly manufactured or obtained fentanyl, and help those in need to recover from substance use disorders. Medication-assisted treatment is recommended for patients struggling with substance abuse, including abuse of illicit and prescription opioids; people who abuse prescription opioids are 40 times more likely to also abuse heroin [11] . Reviewing patients' prescription and illicit substance abuse history prior to starting MAT is advised; subsequently, monitoring PMP data and routine urine drug testing for specific substances (e.g., buprenorphine, heroin, prescription opioids, cocaine, benzodiazepines) is recommended [26, 27] . Increasing first responder, family member, and opioid user access to opioid antagonists (e.g., naloxone) can also reduce overdoses and improve opioid safety [11, 28] .
Addressing pain is an important part of clinical care; it is estimated that 11.2% of people in the United States suffer from chronic pain [29] . While diverse nonopioid treatment options for acute and chronic pain exist (e.g., physical therapy, nonsteroidal anti-inflammatory drugs) and should be considered prior to starting an opioid treatment regimen, the benefits of opioid medications may occasionally outweigh the risks. Given the strong association between prescription opioid abuse and abuse of illicit drugs such as heroin, it is imperative that prescribers and dispensers ensure patients' safety when utilizing opioid medications.
Providers should assess patients' substance abuse history and risk for abuse prior to prescribing opioids and start with the lowest effective dose [30] [31] [32] during a predetermined time frame [30, 32] . Prescribers should monitor the patients' pain intensity [30, 31] , level of functioning [30] [31] [32] , and evidence of aberrant behaviors or adverse effects [30, 31] . It is important for prescribers to ensure that patients receive appropriate pain treatment while preventing or reducing their risk for adverse outcomes. Illicit, nonprescription opioids are not always sought for recreational purposes; sometimes they are sought as an alternate mechanism for pain control.
Additionally, it is recommended that prescribers and dispensers verify patients' prescription drug history prior to dispensing opioids. PMPs are a useful tool for this task. Given the relationship between heroin and prescription opioid abuse [33, 34] , these actions-in conjunction with following guidelines for opioid prescribing-might reduce both heroin and prescription opioid abuse and overdoses. Utilizing PMP data to identify prescribers and dispensers associated with opioid overdose deaths and patients with high MME/day is also recommended.
